Nona Biosciences has developed fully human heavy-chain-only antibody (HCAb) platforms to advance CAR-T therapy design. This poster highlights:
-
- Validation of HCAD-based BCMA-CAR leads with strong cytotoxicity and survival benefits
- Use of lipid nanoparticles (LNPs) to efficiently deliver HCAb-based CAR constructs
- Evidence that fully human VHH CARs streamline development and improve therapeutic potential
Download the full poster to explore data on in vivo validation, optimized delivery, and how this approach opens new avenues for next-generation CAR therapies.
Download our Scientific Poster!